Here, we are influenced by work on bortezomib, the 26S proteosome inhibitor, using multiple myeloma cell lines, such as AMO-1 cells, where it has been established that the therapeutic index of bortezomib depends entirely upon the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, and type I interferon secretion to promote immunogenic cell death [19]. The gene discussed is CGAS; the disease is AL amyloidosis.